-
2024-519655-28-00
5
2026-04-23
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-511985-34-00
6
2026-03-05
Evaluation of the CKD-Epi score to identify a glomerular filtration th
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-521293-34-00
4
2025-12-09
Moderate-to-severe hidradenitis suppurativa
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504670-38-00
4
2023-11-17
Extensive disease Small Cell Lung Cancer
-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2024-510635-21-00
5
2023-05-09
warm autoimmune haemolytic anaemia (wAIHA)
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2024-516215-24-00
4
2026-07-01
TAkayasu ARteritiS
-
2025-522193-37-00
5
2026-06-09
Septic arthritis
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2024-519208-29-00
4
2026-04-02
Pleural mesothelioma
-
2024-514949-11-00
5
2026-03-18
Hypoxemic acute respiratory failure
-
2025-522309-40-00
4
2026-02-11
Non-segmental vitiligo
-
2024-515948-23-00
5
2026-02-06
Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
-
2023-508930-33-00
4
2026-01-30
Non-infectious active cryoglobulinemia vasculitis who are either refra
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2024-518385-26-01
5
2025-12-18
Polymyalgia Rheumatica (PMR)